Thane Wettig
Chief Executive Officer presso FIBROGEN, INC.
Patrimonio netto: 1 M $ in data 31/03/2024
Profilo
Thane Wettig is currently the Chief Executive Officer & Director at FibroGen, Inc. He previously worked as the Chief Commercial Officer at Intarcia Therapeutics, Inc. and as the Vice President-Diabetes Brands Global Marketing at Lilly Diabetes from 2004 to 2009.
Mr. Wettig completed his undergraduate degree and MBA at Washington University in St. Louis.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
FIBROGEN, INC.
0.48% | 22/03/2024 | 470 396 ( 0.48% ) | 1 M $ | 31/03/2024 |
Posizioni attive di Thane Wettig
| Società | Posizione | Inizio |
|---|---|---|
| FIBROGEN, INC. | Chief Executive Officer | 23/07/2023 |
Precedenti posizioni note di Thane Wettig
| Società | Posizione | Fine |
|---|---|---|
| Lilly Diabetes | Corporate Officer/Principal | 01/01/2009 |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
Formazione di Thane Wettig
| Washington University in St. Louis | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| FIBROGEN, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
| Lilly Diabetes |
- Borsa valori
- Insiders
- Thane Wettig
